Search Results - Irving, William L.

  • Showing 1 - 20 results of 20
Refine Results
  1. 1
    Comorbities and medications of patients with chronic hepatitis C under specialist care in the UK

    Comorbities and medications of patients with chronic hepatitis C under specialist care in the UK by Hudson, Benjamin, Walker, Alex J., Irving, William L.

    Published 2017
    Get full text
  2. 2
    Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection

    Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection by Lattimore, Sam, Irving, William L., Collins, Sarah, Penman, Celia, Ramsay, Mary

    Published 2014
    Get full text
  3. 3
    Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: a possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles

    Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: a possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles by Abo-zeid, Yasmin, Mantovani, Giuseppe, Irving, William L., Garnett, Martin.C

    Published 2018
    Get full text
  4. 4
    Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review

    Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review by Walker, Alex J., Peacock, Christian J., Pedergnana, Vincent, Irving, William L.

    Published 2018
    Get full text
  5. 5
    Understanding hepatitis C intervention success: qualitative findings from the HepCATT study

    Understanding hepatitis C intervention success: qualitative findings from the HepCATT study by Harris, Magdalena, Bonnington, Oliver, Harrison, Graham, Hickman, Matthew, Irving, William L.

    Published 2018
    Get full text
  6. 6
    Pretreatment lesions on magnetic resonance imaging in patients with hepatitis C virus infection diagnosed with hepatocellular carcinoma after initiating direct-acting antiviral therapy

    Pretreatment lesions on magnetic resonance imaging in patients with hepatitis C virus infection diagnosed with hepatocellular carcinoma after initiating direct-acting antiviral the... by Scott, Robert A., Aithal, Guruprasad P., Francis, Susan T., Irving, William L.

    Published 2018
    Get full text
  7. 7
    Use of short-tandem repeat (STR) fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies

    Use of short-tandem repeat (STR) fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies by Edwards, Victoria C., McClure, Patrick, Brown, Richard J.P., Thompson, Emma, Irving, William L., Ball, Jonathan K.

    Published 2014
    Get full text
  8. 8
    Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy?

    Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy? by Abo-zeid, Yasmin, Urbanowicz, Richard A., Thomson, Brian J., Irving, William L., Tarr, Alexander W., Garnett, Martin C.

    Published 2018
    Get full text
  9. 9
    Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease

    Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease by Kendall, Timothy, Dolman, Grace, Duff, Catherine, Paish, Emma C., Zaitoun, Abed, Irving, William L., Fallowfield, Jonathan A., Guha, Indra Neil

    Published 2018
    Get full text
  10. 10
    Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitus C virus E2 protein confer noninterfering, additive neutralization

    Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitus C virus E2 protein confer noninterfering, additive neutralization by Tarr, Alexander W., Urbanowicz, Richard A., Jayaraj, Dhanya, Brown, Richard J.P., McKeating, Jane A., Irving, William L., Ball, Jonathan K.

    Published 2012
    Get full text
  11. 11
    Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the Hepatitis C virus E2 protein confer noninterfering, additive neutralization

    Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the Hepatitis C virus E2 protein confer noninterfering, additive neutralization by Tarr, Alexander, W., Urbanowicz, Richard, A., Jayaraj, Dhanya, Brown, Richard, J.P., McKeating, Jane, A., Irving, William L., Ball, Jonathan, K.

    Published 2012
    Get full text
  12. 12
    Cohort profile: the Hepatitis C Virus (HCV) Research UK clinical database and biobank

    Cohort profile: the Hepatitis C Virus (HCV) Research UK clinical database and biobank by McLauchlan, John, Innes, H., Dillon, J.F., Foster, G., Holtham, E., McDonald, S., Wilkes, B., Hutchinson, S.J., Irving, William L.

    Published 2017
    Get full text
  13. 13
    Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis

    Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis by Manouchehrinia, Ali, Tanasescu, Radu, Kareem, Huner, Jerca, Oltita P., Jabeen, Fouzia, Shafei, Rachelle, Breuer, Judith, Neal, Keith R., Irving, William L., Constantinescu, Cris S.

    Published 2017
    Get full text
  14. 14
    The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy

    The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy by Backx, M., Lewszuk, A., White, J.R., Cole, J., Sreedharan, A., van Sanden, S., Diels, J., Lawson, A., Neal, K.R., Wiselka, M.J., Ito, T., Irving, William L.

    Published 2014
    Get full text
  15. 15
    A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance

    A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance by Urbanowicz, Richard A., McClure, Patrick, Brown, Richard J.P., Tsoleridis, Theocharis, Persson, Mats A.A., Krey, Thomas, Irving, William L., Ball, Jonathan K., Tarr, Alexander W.

    Published 2016
    Get full text
  16. 16
    Recombinant human L-ficolin directly neutralizes hepatitis C virus entry

    Recombinant human L-ficolin directly neutralizes hepatitis C virus entry by Hamed, Mohamed R., Brown, Richard J.P., Zothner, Carsten, Urbanowicz, Richard A., Mason, Christopher P., Krarup, Anders, McClure, C. Patrick, Irving, William L., Ball, Jonathan K., Harrison, Mark, Hickling, Timothy P., Tarr, Alexander W.

    Published 2014
    Get full text
  17. 17
    Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

    Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis by Cheung, Michelle C.M., Walker, Alex J., Hudson, Benjamin E., Verma, Suman, McLauchlan, John, Mutimer, David J., Brown, Ashley, Gelson, William T.H., MacDonald, Douglas C., Agarwal, Kosh, Foster, Graham R., Irving, William L.

    Published 2016
    Get full text
  18. 18
    Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

    Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis by Foster, Graham R., Irving, William L., Cheung, Michelle C.M., Walker, Alex J., Hudson, Benjamin E., Verma, Suman, McLauchlan, John, Mutimer, David J., Brown, Ashley, Gelson, William T.H., MacDonald, Douglas C., Agarwal, Kosh

    Published 2016
    Get full text
  19. 19
    SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis

    SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis by Athwal, Varinder S., Pritchett, James, Llewellyn, Jessica, Martin, Katherine, Camacho, Elizabeth, Raza, Sayyid M.A., Phythian-Adams, Alexander, Birchall, Lindsay J., Mullan, Aoibheann F., Su, Kim, Pearmain, Laurence, Dolman, Grace, Zaitoun, Abed M., Friedman, Scott L., MacDonald, Andrew, Irving, William L., Guha, Indra N., Hanley, Neil A., Hanley, Karen Piper

    Published 2017
    Get full text
  20. 20
    MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C

    MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C by Thabet, Khaled, Asimakopoulos, Anastasia, Shojaei, Maryam, Romero-Gomez, Manuel, Mangia, Alessandra, Irving, William L., Berg, Thomas, Dore, Gregory J., Grønbæk, Henning, Sheridan, David, Abate, Maria Lorena, Bugianesi, Elisabetta, Weltman, Martin, Mollison, Lindsay, Cheng, Wendy, Riordan, Stephen, Fischer, Janett, Spengler, Ulrich, Nattermann, Jacob, Wahid, Ahmed, Rojas, Angela, White, Rose, Douglas, Mark W., McLeod, Duncan, Powell, Elizabeth, Liddle, Christopher, van der Poorten, David, George, Jacob, Eslam, Mohammed, Gallego-Duran, Rocio, Applegate, Tanya, Bassendine, Margaret, Rosso, Chiara, Mezzabotta, Lavinia, Leung, Reynold, Malik, Barbara, Matthews, Gail, Grebely, Jason, Fragomeli, Vincenzo, Jonsson, Julie R., Santaro, Rosanna

    Published 2016
    Get full text

Search Tools: